The pharmacokinetics of alfentanil under the conditions of an empirically derived 1 -h continuous infusion of 3ugkg~' mm" 1 , with a bolus of 80 ngkg" 1 , both i.v., were determined in five patients. The distribution half-life (mean±SD) (7.4±3.1min), elimination half-life (86.7± 15.8min), apparent volume of distribu- 
Studies of the pharmacokinetics of single bolus doses of alfentanil have been reported recently (Bovill et al., 1982; Bower and Hull, 1982; Camu et al., 1982; Schuttler and Stoeckel, 1982) . Compared with fentanyl, alfentanil has a smaller volume of distribution, greater binding to plasma proteins, less binding to red cells, a shorter elimination halflife, a slower total body clearance, and is less lipid soluble-characteristics which suggest that alfentanil would be an appropriate drug to give by continuous i.v. infusion.
The purpose of this study was to evaluate an i.v. bolus and infusion regimen as part of a balanced anaesthetic technique, and to determine the pharmacokinetics of alfentanil under these conditions . The bolus and infusion regimen was an empirically derived dose schedule of a bolus of 80 jig kg" 1 and a continuous infusion of 3 ng kg" 1 min 1 .
PATIENTS AND METHODS
Five healthy patients (two male), scheduled for elective surgery under general anaesthesia, consented to participate in this study which was approved by the hospital Ethics committee. The operations were expected to last at least 1 h and to be associated with a blood loss of less than 500 ml. After fasting overnight, the patients received diazepam 10 mg by mouth 1 h before the induction of anaesthesia (thiopentone 400-500 mg i.v.). Intubation of the trachea was facilitated with pancuronium O.Oo^gkg" 1 i.v. Ventilation was controlled with 67% nitrous oxide in oxygen to maintain expired carbon dioxide between 4.5 and 5.5 vol% as measured by a calibrated capnograph. If necessary to maintain unconsciousness, enflurane 0.2-0.5% was added to the inspired mixture until the alfentanil was administered. All i.v. drugs were administered through an i.v. cannula in one arm and 5-ml blood samples for drug analysis were taken from a 16-gauge cannula placed in a large vein in the opposite arm. A bolus injection of alfentanil O.Smgml" 1 , 80 Hgkg" 1 over 30 s (.Kbotu. = 160 jigkg" 1 min" 1 ) and a continuous infusion of alfentanil at a rate of 3 jig kg" 1 min" 1 (^i) were started simultaneously. The infusion fluid was 60 ml of alfentanil 0.25 mgml" 1 solution. The infusion was given for 1 h so that each patient received a total alfentanil dose, bolus plus infusion, of 260ngkg" 1 . Venous blood samples were withdrawn just before, and 2, 5, 10, 15, 30, 45 and 60 min after the start of the drug injection, and 2, 5, 10, 15, 30, 60, 120, 240 and 360 min after the infusion was discontinued. The plasma was separated and stored at -20°C until assayed. Plasma concentrations were measured with a sensitive and specific radioimmunoassay (Michels, Hendricks and Heykants, 1983) by Janssen Pharmaceutica and kinetic parameters were determined by NONLIN analysis (Metzler, 1969) .
Nitrous oxide was discontinued at the end of the operation which was within 10 min of the end of the infusion of alfentanil. Ventilation was assisted with oxygen until the patient was able to maintain ade-© The Macmillan Press Ltd 1983 quate spontaneous ventilation. Every 2 min the same investigator requested that the patient open his eyes. The time that this occurred was noted for later correlation with the plasma concentrations of alf entanil.
RESULTS
The patient characteristics are shown in table I and the measured plasma concentrations for each patient in table II. The time course of the mean plasma concentrations of alfentanil, during and after the infusion, indicate that the decay of the plasma concentrations could be described by a twocompartment model ( fig. 1 ). Plasma concentrations decreased by 30% from their peak values over the first 10 min. Thereafter, the effect of the continuous infusion was a gradual increase in the plasma concentration until the infusion was stopped. No patient responded to painful surgical stimuli during the period of infusion or required any other anaesthetic drug(s). The plasma concentration-time curve was analysed by the NON-LIN program and was divided into three parts: part one was the input of the bolus injection plus the infusion; part two was the infusion minus the elimination of the bolus, and part three was the elimination period. The equations used are presented in the appendix. The calculated pharmacokinetic parameters are presented in table III. The individual patient values and the mean ± standard deviation for the group are indicated. The specific response (plasma concentration-effect relationship) showed that awakening occurred when the plasma concentration decreased by a mean of 68 ±6.4% (range 59-74%) from that measured at the time the infusion was stopped. However, there was considerable variability in the measured plasma concentrations at the time patients opened their eyes to command (178-310 ngml" 1 ).
DISCUSSION
The alfentanil elimination half-life of the present study is in agreement with those reported recently (Bovill et al., 1982; Bower and Hull, 1982; Camu et al., 1982; Schuttler and Stoeckel, 1982) . The volume of distribution (V) and elimination clearance of alfentanil in the present study are in agreement with those reported by Bower and Hull (1982) , but are approximately half those reported by other workers. The plasma concentrations of alfentanil at the times the patients responded to verbal command by opening their eyes were fairly consistent when com- 
FIG. 1. Plasma concentrations of alfentanil after a 30-8 bolus injection of 80 figkg ' and a 1-h continuous infusion at a rate of 3 fig kg"
1 min-1 started simultaneously. Each data point represents the mean ± standard deviation from five patients.
pared with the plasma concentrations at the times the infusion was stopped. However, the variability in individual plasma concentrations was as expected in patients of different ages undergoing surgery and receiving multiple drugs (Bowman and Rand, 1980) . (Stoeckel, Hengstmann and Schuttler, 1979) , there was no rebound increase in the plasma concentration of alfentanil during the elimination period. This suggests that recurrent postoperative ventilatory depression may not be a problem when alfentanil It has been reported that a steady state plasma concentration of 400 ngml" 1 is necessary to provide adequate analgesia with 67% nitrous oxide (Carl C. Hug, jr, personal communication). On the basis of the pharmacokinetic results of the present study, the correct loading dose and maintainance infusion rate to maintain a steady state plasma concentration of -WOngml" 1 has been determined, using the method of Mitenko and Ogilvie (1972) to be 176ngkg~' and 1.3 ngkg" 1 min" 1 , respectively (table IV). The smaller loading dose used in the present study would account for the early decrease in the plasma concentration-time relationship and, together with the higher maintenance infusion used, for the increases in the plasma concentrations observed for the duration of the infusion; together they fortuitously maintained plasma alfentanil concentrations above the 300ngml~' minimum recommended by Bovill and colleagues (1982) . The bolus and infusion procedure recommended above should minimize variations in plasma concentrations, especially those below the therapeutic threshold, during the infusion, and result in a lower plasma concentration at the end of the infusion period and, as a result, more rapid recovery. 
Contrary to observations made for fentanyl

